Preparations to close out the LVAD Cell Therapy Trial are underway. Preparations for a conference call on Tuesday, November 26th and are posed of principal investigators and coordinators, convened to discuss changes to the protocol such as decreased weaning criteria. The DCC released a brief survey to sites that did not participate in the LVAD Stage 1 op AF study and LVAD Cell Therapy Stage 2. To inform site planning for the second stage of LVAD Cell Therapy Trial is ongoing. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network. From an IND perspective, changes to the protocol will be presented to the DSMB during the third week of January 2014. The DSMB will then submit to the FDA for their approval. The protocol will be then submitted to the DSMB during the third week of January 2014. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network. More information on study close processes out will be issued to sites applications.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.

The LVAD Cell Therapy Trial is an open-label trial designed to test the safety and efficacy of a bioprosthetic heart valve for patients with severe aortic valve stenosis. The trial began in 2009 and is currently recruiting patients. The LVAD Cell Therapy Trial is being extended in response to increased interest from the Network.